Evidence map›Paper›PMID 39162954›Full record

ReviewDrugs in R&D2024

Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.

Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore, Alexander Solms, Anita Shah, Pål André Holme, Lone H Poulsen, Karina Meijer and 2 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs in R&D, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mark T RedingCenter for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA.
Shadan LalezariNational Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel.
Gili KenetNational Hemophilia Center, Sheba Medical Center, Tel HaShomer, Israel.
Giovanni Di MinnoRegional Reference Center for Coagulation Disorders, Federico II University Hospital, Naples, Italy.
Jonathan DucoreHemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA.
Alexander SolmsBayer AG, Berlin, Germany.
Anita ShahBayer, Whippany, NJ, USA.
Pål André HolmeDepartment of Haematology, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Lone H PoulsenThe Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark.
Karina MeijerUniversity Medical Center Groningen, Groningen, The Netherlands.
Mindy SimpsonRush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USA.
Maria Elisa MancusoCenter for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. mariaelisa_mancuso@libero.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Damoctocog alfa pegol (BAY 94-9027, Jivi

Indexed as

Factor VIIIHemophilia APolyethylene GlycolsHalf-LifeHumansRandomized Controlled Trials as TopicBAY 94-9027Factor VIIIPolyethylene Glycols

Identifiers

PMID39162954
PMCPMC11456056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.